Table 1Baseline characteristics of study participants (intention-to-treat population)
Characteristic |
Rosuvastatin 20 mg/day (n=21) |
Rosuvastatin 5 mg+ ezetimibe 10 mg/day (n=21) |
P value |
Age, yr |
53.0±11.5 |
50.4±11.6 |
0.48 |
Male sex |
66.7 (14) |
61.9 (13) |
0.75 |
Current smoking, % |
33.3 (7) |
33.3 (7) |
1.00 |
Alcohol drinking, % |
28.6 (6) |
33.3 (7) |
0.74 |
Body mass index, kg/m2
|
25.3±3.0 |
25.9±3.6 |
0.55 |
Waist circumference, cm |
88.5±10.2 |
90.7±11.0 |
0.51 |
Systolic blood pressure, mm Hg |
129.2±11.9 |
128.3±12.6 |
0.81 |
Diastolic blood pressure, mm Hg |
78.2±7.8 |
77.4±11.7 |
0.79 |
Total cholesterol, mg/dL |
234.9±26.9 |
236.5±29.5 |
0.85 |
Triglycerides, mg/dL |
135.5±43.7 |
173.1±64.1 |
0.03 |
HDL-C, mg/dL |
49.4±10.9 |
47.7±10.1 |
0.59 |
LDL-C, mg/dL |
154.2±14.5 |
156.8±24.2 |
0.68 |
Non-HDL-C, mg/dL |
185.4±25.1 |
188.8±30.6 |
0.70 |
ApoB, mg/dL |
128.8±14.0 |
134.9±24.3 |
0.32 |
ApoA1, mg/dL |
150.9±23.3 |
152.8±31.2 |
0.82 |
ApoB/A1 |
0.87±0.16 |
0.93±0.31 |
0.46 |
Fasting plasma glucose, mg/dL |
142.9±41.8 |
144.6±52.2 |
0.91 |
Fasting plasma insulin, μIU/mL |
9.9 (7.3–12.5) |
9.3 (8.2–11.9) |
0.89 |
HbA1c, % |
7.5±1.8 |
7.4±1.7 |
0.87 |
HOMA-IR |
3.36 (2.31–4.24) |
3.11 (2.53–4.34) |
0.87 |
HOMA-B% |
20.6 (16.3–31.6) |
20.8 (17.1–26.2) |
0.92 |
High-sensitivity CRP, mg/L |
0.91 (0.50–2.66) |
0.64 (0.46–1.45) |
0.57 |
Lp(a), mg/mL |
9.4 (4.9–19.7) |
13.7 (5.1–28.1) |
0.57 |
Free fatty acids, μEq/L |
689.7±225.5 |
693.5±274.3 |
0.96 |
Table 2Changes in lipid parameters after 6 weeks treatment (per-protocol population)
Variable |
Rosuvastatin 20 mg/day (n=20) |
Rosuvastatin 5 mg+ezetimibe 10 mg/day (n=16) |
P value |
Total cholesterol, mg/dL |
−99.0±28.0a
|
−98.4±28.7a
|
0.77 |
Triglycerides, mg/dL |
−10.5 (−37.5 to 29.5) |
−49.5 (−108.5 to −27.5)a
|
0.01 |
HDL-C, mg/dL |
0.5 (−3.0 to 6.8) |
−0.5 (−1/8 to 7.5) |
0.99 |
LDL-C, mg/dL |
−94.3±15.4a
|
−89.9±22.7a
|
0.54 |
Non-HDL-C, mg/dL |
−100.8±25.7a
|
−98.9±26.3a
|
0.79 |
ApoB, mg/dL |
−62.0±20.9a
|
−66.8±21.6a
|
0.86 |
ApoA1, mg/dL |
8.0 (−1.8 to 21.0)b
|
5.0 (−14.8 to 15.0) |
0.20 |
ApoB/A1 |
−0.44 (−0.56 to −0.34)a
|
−0.38 (−0.54 to −0.32)a
|
0.58 |
Lp(a), mg/mL |
0.50 (−0.93 to 4.60) |
0.00 (−5.08 to 7.13) |
0.67 |
Free fatty acids, μEq/L |
0.0 (−136.8 to 146.0) |
−170.5 (−353.0 to 0.8)c
|
0.05 |
Table 3Changes in other parameters after 6 weeks of treatment (per-protocol population)
Variable |
Rosuvastatin 20 mg/day (n=20) |
Rosuvastatin 5 mg+ezetimibe 10 mg/day (n=16) |
P value |
Systolic blood pressure, mm Hg |
−5.0 (−7.8 to 3.5) |
−4.5 (−15.5 to 4.3) |
0.99 |
Diastolic blood pressure, mm Hg |
−0.5 (−5.0 to 2.8) |
1.0 (−6.8 to 6.0) |
0.81 |
Body mass index, kg/m2
|
−0.1 (−0.7 to 0.2) |
0.0 (−0.7 to 0.3) |
0.79 |
Waist circumference, cm |
0.0 (−2.0 to 2.0) |
−0.9 (−2.6 to 2.5) |
0.67 |
Fasting plasma glucose, mg/dL |
−1.0 (−12.3 to 12.0) |
−2.0 (−41.3 to 10.8) |
0.50 |
Fasting plasma insulin, μIU/mL |
0.1 (−2.0 to 1.3) |
0.3 (−1.1 to 1.5) |
0.84 |
HbA1c, % |
−0.2 (−0.7 to 0.3) |
−0.3 (−0.8 to 0.2) |
0.54 |
HOMA-IR |
0.00 (−1.12 to 0.88) |
−0.23 (−1.50 to 0.36) |
0.39 |
HOMA-B% |
0.0 (−4.1 to 3.7) |
−0.3 (−4.1 to 8.9) |
0.79 |
High-sensitivity CRP, mg/L |
−0.49 (−1.17 to 0.18) |
−0.15 (−0.38 to 0.16) |
0.35 |
Abnormal liver function test, % |
15.0 (3) |
12.5 (2) |
1.00 |
Myalgia, % |
0 |
0 |
1.00 |
Creatine kinase ≥UNL, % |
20.0 (4) |
0 |
0.11 |